PDCD1 and neoplasm: In vivo, following treatment with AZD6738 and cisplatin, flow cytometry analysis performed in tumor cells revealed an increased infiltration of CD3<sup>+</sup> and CD8<sup>+</sup> T cells, with the triple combination of AZD6738, cisplatin, and anti-PD1 achieving the strongest antitumor effect.